Cardiovascular Drugs Market: By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel and Region Forecast 2020-2031
Cardiovascular Drugs Market size was valued at US$ 149.9 billion in 2024 and is expected to reach US$ 197.2 billion by 2031, growing at a significant CAGR of 4.0% from 2025-2031. Cardiovascular drugs are the medications used in the treatment of various cardiovascular diseases. Cardiovascular diseases (CVD) include coronary artery diseases (CAD), myocardial infarction, angina pectoris, hypertension, cardiomyopathy, congenital heart disease, cardiac arrhythmia, peripheral artery diseases, atherosclerosis, and venous thrombosis among others. Majority of the cardiovascular diseases are preventable with cardiovascular drugs, however, in frequent conditions death may occur due to cardiovascular diseases. Global Market has a tremendous growth rate over the forecast years owing to an increase in the prevalence of various cardiovascular diseases and a rise in R&D activities for the innovation of newer drugs.
According to the World Health Organization 2015, approximately 17.7 Mn deaths occurred due to cardiovascular diseases around the world. Moreover, government support to control the diseases, rise in funding from public and private sectors for R&D activities, and patent expiration of blockbusters are bolster the cardiovascular drugs market. Furthermore, acquisitions and mergers, product approvals, and promising pipeline drugs might upsurge the revenue of the cardiovascular drugs market.
Study Period
2025-2031Base Year
2024CAGR
4.0%Largest Market
North-AmericaFastest Growing Market
Europe
Increase in the prevalence of cardiovascular diseases, for instance, according to World health organization 2015, approximately 17.7 Mn people died from cardiovascular diseases around the globe, rise in R&D activities for the innovation of newer cardiovascular drugs, government support to increase the awareness about the cardiovascular diseases and treatment are anticipated to fuel the cardiovascular drugs market. Moreover, change in lifestyle, promising product pipeline, rise in prevalence of obesity, and wider access to cardiovascular drugs in the market are anticipated to propel the market. However, stringent regulatory guidelines for the product approval, high cost of treatment, and adverse effects associated with the medications are hampering the growth of cardiovascular drugs market.
North America accounted for significant share owing to increase in the prevalence of cardiovascular diseases (according to centers for Disease Control and Prevention, approximately 610,000 deaths occur due to various heart diseases in U.S. every year) and rise in R&D activities in North America region. Europe exhibiting lucrative growth due to increase in incidences of cardiovascular diseases majorly in Germany, Russia, UK, Ukraine, and Italy. Asia Pacific is growing at notable rate due to increase in geriatric population in India, China, and Japan, rise in medical tourism in Asia Pacific countries, and government support for the prevention of cardiovascular diseases in various countries. Latin America has significant growth which is attributed to increase in prevalence of cardiovascular diseases in Chile, Argentina, and Brazil. Middle East and Africa is growing due to expansion of business by market players, rise in prevalence of cardiovascular diseases, and government support to protect the public health.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 149.9 billion |
|
Market Size in 2031 |
US$ 197.2 billion |
|
Market CAGR |
4.0% |
|
By Indication |
|
|
By Drugs Class |
|
|
By Route of Administration |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Cardiovascular drugs market size was valued at US$ 149.9 billion in 2024 and is expected to reach US$ 197.2 billion by 2031, growing at a significant CAGR of 4.0%.
The Cardiovascular Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Cardiovascular Drugs Market key players are Capsa Solutions LLC (U.S.), Ergotron, Inc. (Melrose Industries plc) (UK), Enovate Medical (U.S.), Villard (France), Parity Medical (UK), InterMetro Industries Corp. (Emerson Electric) (U.S.), Humanscale Healthcare (U.S.), ITD GmBH (Germany), Compucaddy (U.S.), Advantech Co., Ltd. (China), Bytech Healthcare Ltd. (U.K.)
| 1.Executive Summary |
| 2.Global Cardiovascular Drugs Market Introduction |
| 2.1.Global Cardiovascular Drugs Market - Taxonomy |
| 2.2.Global Cardiovascular Drugs Market - Definitions |
| 2.2.1.Indication |
| 2.2.2. Drugs Class |
| 2.2.3.Route of Administration |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3.Global Cardiovascular Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cardiovascular Drugs Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cardiovascular Drugs Market By Indication, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Hypertension |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Congestive Heart disease |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Angina pectoris |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Myocardial Ischemia |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Peripheral Artery Diseases |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Atherosclerosis |
| 5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Cardiomyopathy |
| 5.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Others |
| 5.8.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 6.Global Cardiovascular Drugs Market By Drugs Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Calcium Channel Blockers |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Angiotensin Converting Enzyme (ACE) inhibitors |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Angiotensin-II Receptor antagonists |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Diuretics |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Lipid-lowering drugs |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Beta-adrenergic Blocking Agents |
| 6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Vasodilators |
| 6.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Anti-platelet Agents |
| 6.8.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 6.9. Others |
| 6.9.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.9.3. Market Opportunity Analysis |
| 7.Global Cardiovascular Drugs Market By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Buccal/sublingual |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Intravenous |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Oral |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.Global Cardiovascular Drugs Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9.Global Cardiovascular Drugs Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Cardiovascular Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Hypertension |
| 10.1.2.Congestive Heart disease |
| 10.1.3.Angina pectoris |
| 10.1.4.Myocardial Ischemia |
| 10.1.5.Peripheral Artery Diseases |
| 10.1.6.Atherosclerosis |
| 10.1.7.Cardiomyopathy |
| 10.1.8.Others |
| 10.2. Drugs Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Calcium Channel Blockers |
| 10.2.2.Angiotensin Converting Enzyme (ACE) inhibitors |
| 10.2.3.Angiotensin-II Receptor antagonists |
| 10.2.4.Diuretics |
| 10.2.5.Lipid-lowering drugs |
| 10.2.6.Beta-adrenergic Blocking Agents |
| 10.2.7.Vasodilators |
| 10.2.8.Anti-platelet Agents |
| 10.2.9.Others |
| 10.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oral |
| 10.3.2.Buccal/sublingual |
| 10.3.3.Intravenous |
| 10.3.4.Oral |
| 10.3.5.Others |
| 10.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacies |
| 10.4.2.Retail Pharmacies |
| 10.4.3.Online Pharmacies |
| 10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Cardiovascular Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Hypertension |
| 11.1.2.Congestive Heart disease |
| 11.1.3.Angina pectoris |
| 11.1.4.Myocardial Ischemia |
| 11.1.5.Peripheral Artery Diseases |
| 11.1.6.Atherosclerosis |
| 11.1.7.Cardiomyopathy |
| 11.1.8.Others |
| 11.2. Drugs Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Calcium Channel Blockers |
| 11.2.2.Angiotensin Converting Enzyme (ACE) inhibitors |
| 11.2.3.Angiotensin-II Receptor antagonists |
| 11.2.4.Diuretics |
| 11.2.5.Lipid-lowering drugs |
| 11.2.6.Beta-adrenergic Blocking Agents |
| 11.2.7.Vasodilators |
| 11.2.8.Anti-platelet Agents |
| 11.2.9.Others |
| 11.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oral |
| 11.3.2.Buccal/sublingual |
| 11.3.3.Intravenous |
| 11.3.4.Oral |
| 11.3.5.Others |
| 11.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacies |
| 11.4.2.Retail Pharmacies |
| 11.4.3.Online Pharmacies |
| 11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Cardiovascular Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Hypertension |
| 12.1.2.Congestive Heart disease |
| 12.1.3.Angina pectoris |
| 12.1.4.Myocardial Ischemia |
| 12.1.5.Peripheral Artery Diseases |
| 12.1.6.Atherosclerosis |
| 12.1.7.Cardiomyopathy |
| 12.1.8.Others |
| 12.2. Drugs Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Calcium Channel Blockers |
| 12.2.2.Angiotensin Converting Enzyme (ACE) inhibitors |
| 12.2.3.Angiotensin-II Receptor antagonists |
| 12.2.4.Diuretics |
| 12.2.5.Lipid-lowering drugs |
| 12.2.6.Beta-adrenergic Blocking Agents |
| 12.2.7.Vasodilators |
| 12.2.8.Anti-platelet Agents |
| 12.2.9.Others |
| 12.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oral |
| 12.3.2.Buccal/sublingual |
| 12.3.3.Intravenous |
| 12.3.4.Oral |
| 12.3.5.Others |
| 12.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacies |
| 12.4.2.Retail Pharmacies |
| 12.4.3.Online Pharmacies |
| 12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Cardiovascular Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Hypertension |
| 13.1.2.Congestive Heart disease |
| 13.1.3.Angina pectoris |
| 13.1.4.Myocardial Ischemia |
| 13.1.5.Peripheral Artery Diseases |
| 13.1.6.Atherosclerosis |
| 13.1.7.Cardiomyopathy |
| 13.1.8.Others |
| 13.2. Drugs Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Calcium Channel Blockers |
| 13.2.2.Angiotensin Converting Enzyme (ACE) inhibitors |
| 13.2.3.Angiotensin-II Receptor antagonists |
| 13.2.4.Diuretics |
| 13.2.5.Lipid-lowering drugs |
| 13.2.6.Beta-adrenergic Blocking Agents |
| 13.2.7.Vasodilators |
| 13.2.8.Anti-platelet Agents |
| 13.2.9.Others |
| 13.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oral |
| 13.3.2.Buccal/sublingual |
| 13.3.3.Intravenous |
| 13.3.4.Oral |
| 13.3.5.Others |
| 13.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacies |
| 13.4.2.Retail Pharmacies |
| 13.4.3.Online Pharmacies |
| 13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Cardiovascular Drugs Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 14.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Hypertension |
| 14.1.2.Congestive Heart disease |
| 14.1.3.Angina pectoris |
| 14.1.4.Myocardial Ischemia |
| 14.1.5.Peripheral Artery Diseases |
| 14.1.6.Atherosclerosis |
| 14.1.7.Cardiomyopathy |
| 14.1.8.Others |
| 14.2. Drugs Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Calcium Channel Blockers |
| 14.2.2.Angiotensin Converting Enzyme (ACE) inhibitors |
| 14.2.3.Angiotensin-II Receptor antagonists |
| 14.2.4.Diuretics |
| 14.2.5.Lipid-lowering drugs |
| 14.2.6.Beta-adrenergic Blocking Agents |
| 14.2.7.Vasodilators |
| 14.2.8.Anti-platelet Agents |
| 14.2.9.Others |
| 14.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oral |
| 14.3.2.Buccal/sublingual |
| 14.3.3.Intravenous |
| 14.3.4.Oral |
| 14.3.5.Others |
| 14.4. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacies |
| 14.4.2.Retail Pharmacies |
| 14.4.3.Online Pharmacies |
| 14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Capsa Solutions LLC (U.S.) |
| 15.2.2.Ergotron, Inc. (Melrose Industries plc) (UK) |
| 15.2.3.Enovate Medical (U.S.) |
| 15.2.4.Villard (France) |
| 15.2.5.Parity Medical (UK) |
| 15.2.6.InterMetro Industries Corp. (Emerson Electric) (U.S.) |
| 15.2.7.Humanscale Healthcare (U.S.) |
| 15.2.8.ITD GmBH (Germany) |
| 15.2.9.Compucaddy (U.S.) |
| 15.2.10.Advantech Co., Ltd. (China) |
| 15.2.11.Bytech Healthcare Ltd. (U.K.) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
